Non-specific symptoms-based pathways for diagnosing less common cancers in primary care: a service evaluation

INTRODUCTION

Rare and less common cancers (hereafter ‘less common cancers’) account for almost half of all cancer diagnoses in England and over half of all cancer deaths.\(^{1,2}\) This broad term incorporates >200 different tumour types, excluding the four most common malignancies: breast, colorectal, lung, and prostate cancers (hereafter ‘common cancers’).\(^{3}\)

With the exception of cervical cancer, there is currently no established screening programme for less common cancers,\(^{4}\) and recognition of disease relies on the development and presentation of symptoms.\(^{5-7}\) In many cases, these cancers present with non-specific symptoms, which can also originate from multiple benign conditions.\(^{8,9}\) For example, unexpected weight loss is associated with several cancers at all cancer stages but may also arise from serious and non-serious diagnoses associated with a wide range of body systems.\(^{10-13}\) Additionally, the relative scarcity of less common cancers often makes the risk of cancer in symptomatic patients lower than the UK’s recommended 3% threshold for urgent cancer investigation, even when symptoms are highly specific to the cancer.\(^{9,10,14}\) The range of possible conditions and the low likelihood of cancer complicates the choice and timing of diagnostic investigation in primary care.

The diagnostic process for patients diagnosed with less common cancers, as well as those presenting with non-specific symptoms, is often characterised by multiple primary care consultations, investigations, and referrals.\(^{15-17}\) Lengthy intervals from presentation to diagnosis are common,\(^{6,16,17,18}\) as is diagnosis by emergency presentation,\(^{16,19-22}\) with both being associated with high rates of advanced stage diagnosis,\(^{16}\) worse survival,\(^{21}\) and a poorer experience of care.\(^{22}\)

A Multidisciplinary Diagnostic Centre (MDC) approach was piloted in England from December 2016, establishing a dedicated pathway for patients presenting with non-specific symptoms indicative of possible cancer. An evaluation by the Accelerate Coordinate Evaluate (ACE) Programme, which aimed to improve cancer pathways and associated outcomes through the provision of evidence-based information and support,\(^{23}\) demonstrated that the MDC approach diagnosed a broad range of cancers, including a notable proportion of less common cancers.\(^{10}\) The aim of this study was to examine the less common cancers identified during the MDC pilots in detail and to consider whether such an approach has benefit for the diagnosis of these cancers.

METHOD

MDC projects

The ACE Programme evaluation comprised five projects in England, incorporating 10 operational MDC pilot sites (one in Airedale, Yorkshire and the Humber; five in the East Midlands; one in the South Central region; one in South West England; and one in Wales). The ACE Programme evaluation comprised five projects in England, incorporating 10 operational MDC pilot sites (one in Airedale, Yorkshire and the Humber; five in the East Midlands; one in the South Central region; one in South West England; and one in Wales). Place, London E20 1JQ, UK.

Address for correspondence

Dave Chapman, Cancer Research UK, 2 Redman Place, London E20 1JQ, UK.

Email: dave.chapman@cancer.org.uk

Submitted: 15 December 2020; Editor’s response: 5 March 2021; final acceptance: 7 April 2021

©The Authors

This is the full-length article (published online 21 Sep 2021) of an abridged version published in print. Cite this version as: Br J Gen Pract 2021; DOI: https://doi.org/10.3399/BJGP.2020.1108
How this fits in

Almost half of all cancer diagnoses in England are of less common cancer types, many of which can be characterised by non-specific symptoms presentation, long diagnostic intervals and poor clinical outcomes. Five Multidisciplinary Diagnostic Centres (MDCs) were piloted across 10 English sites as a rapid referral route for the investigation of primary care patients with non-specific cancer symptoms. Most cancers diagnosed by the MDCs were ‘less common’ cancers comprising >30 different tumour types. These cancers typically have long diagnostic intervals and have poor clinical outcomes. The broad range of less common cancers diagnosed rapidly by MDCs emphasises the value of diagnostic pathways that aim to establish the cause of symptoms instead of ruling out individual tumour types.

Two in Greater Manchester, one in Leeds, five in London, and one in Oxford. Projects were established to assess a dedicated urgent referral route for patients presenting with a predetermined range of non-specific symptoms for which there was no clear diagnostic approach. The pathway predominantly offered a single referral route for primary care, although a number of projects also allowed a smaller volume of referrals from other agencies. Individual hospital sites were launched at different times from December 2016 to January 2018. To reflect the evaluation’s design, programme-funded activity with the MDC pilots concluded on 31 March 2019.

Referral criteria

MDC project referrals were limited to adult patients aged ≥18 years (in Oxford ≥40 years), presenting with non-specific but concerning symptoms, such as unexplained weight loss, non-specific pain, unexplained appetite loss, and persistent fatigue. Eligibility criteria varied at project level (see Supplementary Box S1 for details), but all projects focused exclusively on patients of clinical concern whose non-specific symptoms were potentially indicative of cancer or other serious disease. To be eligible for referral, the patient’s symptoms also had to be insufficiently clear to identify an appropriate tumour-specific urgent referral pathway. Patients with previous cancers were considered eligible for referral, provided that they had non-specific symptoms only.

Data collection and analysis

A programme dataset was agreed for all MDC projects to ensure a uniform approach to data collection. Data items were based mainly on the English cancer outcomes and services dataset, with additional project-specific items focusing on secondary care presentation, diagnostic process of cancers, and other diseases. Data management arrangements varied by MDC project, and used a combination of local healthcare IT systems and bespoke data systems, with data items collected as close to real-time as possible. Minor recoding was applied by programme evaluators to align the data for analysis.

Simple descriptive and comparative statistics were used, including $\chi^2$ tests for proportions and $t$-tests for means where appropriate, which concentrate on diagnoses of less common cancers within this referral cohort. These have been aggregated to a programme level to provide greater scope for analysis. No formal power calculation was made relating to the expected cancer yield.

This study on less common cancers, which covers MDC pathway activity from December 2016 to March 2019, is one of several pathway analyses and contributes to existing evidence on initial MDC results. Further analyses are planned on MDC diagnostic activity and will consider the overall use of computed tomography as a diagnostic investigation and any impact on pathway time, in addition to the pathway’s diagnosis of non-cancer disease.

Although common cancers have dedicated referral pathways in place, and often present with recognised high-risk site-specific symptoms, patients with these cancers may experience non-specific symptoms, and thus enter the MDC pathway. As the pathway aims to provide a route to diagnosis for symptomatic patients whose cancer is indistinguishable at point of presentation, data on the presentation of common cancers have been included to reflect the difficulty facing the referrer.

A list of symptoms was identified in the dataset and developed with clinical guidance to describe patients whose presentation was suggestive of cancer but did not indicate a specific diagnostic approach. This range of symptoms included some conditions and signs that were not strictly symptoms (see Supplementary Box S2 for details).

RESULTS

From December 2016 to March 2019, 5134 patients were referred to the pilot MDCs. Of a total 378 cancers diagnosed, 218 (58%) were less common cancers (Table 1); therefore, the MDC pathway recorded an overall conversion rate of 7%, with 4%
of the cancers diagnosed being of less common cancer types. The most common diagnoses related to upper gastrointestinal (39%), haematological (25%), and urological (14%) cancers. For five cancers, a confirmed diagnosis was recorded but without additional information on tumour site; these five cancers were excluded from analyses as details of their final diagnoses were unavailable.

In addition to cancers diagnosed, 2060 patients were diagnosed with at least one non-cancer condition. Based on the overall number of diseases recorded (n = 2383), most cases (n = 989; 42%) related to conditions of the digestive system, including gastritis and duodenitis, and diverticular disease. A variety of other non-cancer disease was evident, including conditions relating to abnormal clinical and laboratory findings (n = 279; 12%) [mainly abnormal findings on diagnostic imaging of the lungs], and respiratory disease (n = 170; 7%), including diagnoses of bronchiectasis, emphysema, and other interstitial pulmonary disease. Diseases of the genitourinary system (n = 166; 7%) were also diagnosed, as were several types of benign neoplasm (n = 130; 5%) [data not shown].

Table 2 describes the age and presenting features of patients diagnosed with cancer in the MDC. Symptoms accounting for <5% of symptoms overall have been grouped and classified as ‘other’.

Patients diagnosed with less common cancers had a median age of 74 years (range 30–93 years) [data not shown]. The most common reasons for referral to the MDC for less common and for common cancers, respectively, were: weight loss (26% vs 27%), GP ‘clinical suspicion’ (17% vs 20%), nausea/appetite loss (14% vs 14%), and pain (11% vs 11%) [Table 2]. However, there was no difference in the association between the reason for referral and a diagnosis of a common or less common cancer (χ² = 0.19, with 7 degrees of freedom). Most patients (68%) diagnosed with less common cancers presented with ≥2 non-specific symptoms, with the most common pairings being ‘weight loss and nausea’ (n = 57), and ‘weight loss and GP ‘clinical suspicion’ (n = 57) [data not shown]. Based on 210 completed patient records, 25% of patients overall had ≥3 consultations with their GP before referral [23% less common; 28% common] [Table 2].

Table 3 describes the presenting features of patients diagnosed with the three most frequently diagnosed less common cancers: kidney cancer, non-Hodgkin’s lymphoma, and pancreatic cancer. Variation was noted at a tumour-specific level, with kidney cancers more commonly diagnosed in patients aged ≤75 years, having also presented with higher proportions of weight loss (33%) and fatigue (13%), in addition to a lower proportion of GP ‘clinical suspicion’ (9%) [Table 3]. The proportion of GP ‘clinical suspicion’ was highest for diagnoses of non-Hodgkin’s lymphoma (21%), and rates of nausea/appetite loss were higher in pancreatic cancers (17%). Non-Hodgkin’s lymphoma was associated with higher
**Table 2. Presenting features of Multidisciplinary Diagnostic Centre patients by cancer type**

| Presenting feature                      | Less common cancers (all) | Common cancers |
|----------------------------------------|---------------------------|----------------|
|                                        | n | % | n | % |
| **Patient age range, years**           |   |   |   |   |
| <50                                    | 7 | 3 | 5 | 3 |
| 50–75                                  | 114 | 52 | 78 | 50 |
| >75                                    | 97 | 44 | 72 | 46 |
| All cases                              | 218 | — | 155 | — |
| **Presenting feature**                 |   |   |   |   |
| Weight loss                            | 132 | 26 | 99 | 27 |
| GP ‘clinical suspicion’                 | 90 | 17 | 74 | 20 |
| Nausea/appetite loss                   | 71 | 14 | 52 | 14 |
| Pain                                   | 58 | 11 | 40 | 11 |
| Fatigue                                | 47 | 9 | 39 | 10 |
| Abnormal test results (e.g., bloods or urine) | 30 | 6 | 26 | 7 |
| 'Other' symptoms (with <5% instances)* | 59 | 11 | 29 | 8 |
| **Total symptoms recorded**            | 516 | 100 | 373 | 100 |

*Other symptoms include: patient/family concern; general condition; respiratory problem; jaundice; bloating; change in bowel habit; lymphadenopathy; thrombocytosis; hypercalcaemia; and deep vein thrombosis. Despite being considered a site-specific symptom, jaundice was included as a referral criterion in London MDC to reflect locally determined clinical priorities. MDC = Multidisciplinary Diagnostic Centre.

**Table 3. Presenting features of Multidisciplinary Diagnostic Centre patients diagnosed with kidney, non-Hodgkin’s lymphoma, and pancreatic cancers**

| Presenting feature                      | Kidney (C64) | Non-Hodgkin’s lymphoma (C82–C86, C96) | Pancreas (C25) |
|----------------------------------------|--------------|----------------------------------------|----------------|
|                                        | n | % | n | % | n | % |
| **Patient age range, years**           |   |   |   |   |   |   |
| <50                                    | — | — | — | — | — | — |
| 50–75                                  | 16 | 64 | 16 | 50 | 22 | 51 |
| >75                                    | 9 | 36 | 16 | 50 | 21 | 49 |
| All cases                              | 25 | 100 | 32 | 100 | 43 | 100 |
| **Presenting feature**                 |   |   |   |   |   |   |
| Weight loss                            | 18 | 33 | 20 | 25 | 29 | 26 |
| GP ‘clinical suspicion’                 | 5 | 9 | 17 | 21 | 18 | 16 |
| Nausea/appetite loss                   | 7 | 13 | 11 | 14 | 19 | 17 |
| Pain                                   | 5 | 9 | 8 | 10 | 16 | 14 |
| Fatigue                                | 7 | 13 | 5 | 6 | 9 | 8 |
| Abnormal test results (e.g., bloods or urine) | 3 | 6 | 6 | 7 | 8 | 7 |
| Anaemia                                | 5 | 9 | 6 | 7 | 3 | 3 |
| 'Other' symptoms (with <5% instances overall)* | 4 | 7 | 8 | 10 | 10 | 9 |
| **Total symptoms recorded**            | 54 | 100 | 81 | 100 | 112 | 100 |

*Other symptoms include: patient/family concern; general condition; respiratory problem; jaundice; bloating; change in bowel habit; lymphadenopathy; thrombocytosis; hypercalcaemia; and deep vein thrombosis. Despite being considered a site-specific symptom, jaundice was included as a referral criterion in London MDC to reflect locally determined clinical priorities. MDC = Multidisciplinary Diagnostic Centre.

The MDC pathway recorded an overall cancer conversion rate of 7%, with over half the diagnoses being of less common cancers (an identification rate of 4% for these cancers). An MDC referral therefore selects a population with an overall cancer positive predictive value exceeding the 3% threshold. This study has demonstrated that a dedicated urgent referral pathway focusing on non-specific symptoms rapidly identified a broad range of less common cancers, with >30 different tumour types detected from a total of 218 less common cancers. The MDC pathway recorded an overall cancer conversion rate of 7%, with over half the diagnoses being of less common cancers (an identification rate of 4% for these cancers). An MDC referral therefore selects a population with an overall cancer positive predictive value exceeding the 3% threshold. Crucially, it provides a pathway for the diagnosis of rarer cancers that individually fall beneath this 3% threshold, but are collectively above it. MDC referral can therefore support primary care case management for patients with symptoms of possible cancer that do not qualify for an urgent site-specific referral.

**DISCUSSION**

Summary

This study has several limitations. The MDC provides a referral route for a new cohort of patients, for whom a direct comparator is not available, and this study examines rates of presentation with ≥2 non-specific symptoms. Because of small sample sizes; however, this information is provided for descriptive purposes only. Table 4 provides details of the duration from GP urgent referral to the start of any cancer treatment. Data on interval times from GP urgent referral to start of cancer treatment were only available for 135 of 218 (62%) less common cancer diagnoses. Interval times have been provided at tumour site level in cases where there was a sufficient number of cases to support analysis. In some instances, the number of cases was too small to calculate the centiles reliably. Rates have been provided for median, interquartile range, and 90% centile relating to the pathway’s treatment interval. As these figures respectively include and compensate for outlier records, and provide a figure representative of 90% of the pathway’s activity, they collectively provide a balanced and robust representation of pathway time to cancer treatment.

Table 5 shows the stage distribution of cancers diagnosed in the MDC, and indicates that most diagnoses were of a late stage (III/IV) [79%]. However, a notable proportion of early-stage diagnoses were recorded for these cancers, including for kidney cancers [29%].

**Strengths and limitations**

This study has several limitations. The MDC provides a referral route for a new cohort of patients, for whom a direct comparator is not available, and this study examines
the diagnosis of less common cancers, for which national statistical information is less complete than for common cancers. Both of these factors have tempered judgements on the MDC’s possible impact compared with existing pathways for individual less common cancers. Analyses in this study have also been restricted by the relatively small numbers of some less common cancers, although this is a challenge common to diagnostic studies of any uncommon disease. 28-29 Although presentation with non-specific symptoms, both individually and in combination, has been considered, it has not been possible to ascribe any significance to these analyses as a result of the level of bias introduced into the study by the establishment of the pathway’s referral criteria. Therefore, while the presence of these symptoms will be heightened in the study, it is not possible to extrapolate this to a wider population.

A direct comparison with national 62-day wait performance was hampered by a lack of published data at tumour site level, and by the MDC’s unique focus on non-specific symptoms as a patient cohort, meaning that a viable comparator for the pathway’s treatment interval could not be established. Because of the time-limited nature of the evaluation, judgements regarding the longer-term impact of the pathway on patient outcomes have not been possible, but further research into this area would be of great value. Finally, the study focuses on the results of a service evaluation and,
Ethical approval
The ACE evaluation was classified as a service evaluation and was therefore not subject to ethics approval.

Provenance
Freely submitted; externally peer reviewed.

Competing interests
The authors have declared no competing interests.

Contributors
Airedale MDC pilot: Alan Hart Thomas, respiratory consultant; Dawn Gulliford, cancer patient services manager; Helena Rolfe, cancer lead GP; and Airedale MDC clinical team. Greater Manchester MDC pilots: Matthias Hohmann, Oldham Clinical Commissioning Group GP cancer lead; Chris Repperday, data analyst, Greater Manchester Cancer Alliance; Susan Sykes, senior programme manager, Greater Manchester Cancer Alliance; Sarah Taylor, Greater Manchester Cancer Alliance (formerly London Cancer, Outcomes, North Central and East London MDC had a lead in early diagnosis); Rob Turner, consultant clinical oncologist; and Leeds ACE MDC clinical team and steering group. London MDC pilots: Mush Ahmad, data manager; Felicity Carson, senior project manager; Donna Chung, head of Centre for Cancer Outcomes, North Central and East London Cancer Alliance (formerly London Cancer, hosted by UCL Partners); David Graham, consultant gastroenterologist; Andrew Millar, consultant gastroenterologist; Sara Taiyari, senior project manager; and London MDC clinical teams. Oxford MDC pilot: Claire Friedemann Smith, Suspected CANcer pathway (SCAN) researcher; Fergus Gleeson, consultant radiologist; Shelley Hayles, planned care and cancer clinical lead; Zoe Kaveney, senior project manager; Brian D Nicholson, Macmillan GP and senior clinical researcher; and Oxford MDC clinical team.

Comparison with existing literature
Other studies have examined the presenting features and diagnostic pathways of several less common cancers. Many of these have indicated that less common cancers are subject to long diagnostic intervals and have poor clinical outcomes regarding stage and mortality. Similarly, some recent studies have considered the merits of diagnostic pathways for non-specific symptoms, albeit with a wider focus on cancer overall. The current study adds to this body of evidence by considering the impact of non-site-specific symptomatic referral on the diagnosis of a broad range of less common cancers.

Implications for research and practice
The challenge facing primary care in diagnosing less common cancers presenting with non-specific symptoms is well documented. As an urgent referral pathway for non-specific symptoms, the MDC diagnosed a higher proportion of less common cancers than common cancers ($n = 218$ versus $n = 155$). This was anticipated because presentation with non-specific symptoms is considered normal for several less common cancers, including some of those frequently diagnosed in the MDC; for example, upper gastrointestinal (20% non-specific, 7% characteristic) and haematology (12% non-specific, 8% characteristic), compared with breast and prostate cancer (1% non-specific, 16% characteristic; 18% non-specific, 22% characteristic, respectively, although latter figures relate to urological cancers as a whole).

In this study, 25% of patients in the MDC had ≥3 GP consultations before referral. This figure is below the equivalent rate of 32% for patients with non-specific symptoms reported in the National Cancer Diagnosis Audit, and is suggestive of a reduction in pre-referral consultation activity for this cohort. As the number of consultations before referral has been shown to have validity as a measure of the wider primary care interval, it is arguable that such a reduction via the MDC pathway could support faster diagnosis for some less common cancers, and for patients with non-specific symptoms overall.

In addition to cancer diagnoses, >2000 patients were diagnosed with at least one non-cancer condition, with these diagnoses representative of a broad range of non-malignant disease. As non-specific symptoms can potentially stem from multiple benign and/or serious conditions, the MDC’s focus on resolving symptoms rather than ruling out specific disease enables such a spectrum of diagnoses to occur. This approach can also support connectivity across the surrounding healthcare system through informed onward referral at point of diagnosis within the MDC, and may have benefit regarding ongoing patient surveillance for certain diagnosed conditions.

At a programme level, a median time of 57 days from GP urgent referral to treatment was recorded for less common cancers in the MDC, which is in line with the national 62-day wait standard. Treatment intervals varied by tumour site, with notably shorter median intervals reported for sarcoma, upper gastrointestinal, and ‘other’ cancers, but longer intervals identified for haematology and urology. A partial comparison against national 62-day wait compliance suggests the MDC is faster for oesophago-gastric cancers (75% MDC; 71% England), but moderately slower for other ‘selected’ cancer sites (60% MDC; 69% England). As the study relates to activity in pilot sites, it is plausible that these interval times may improve as the pathway matures and becomes fully embedded and resourced. Cumulatively, by reducing pre-referral activity and providing a swift overall time to treatment, the MDC may also lessen the chance of diagnosis via emergency presentation, which is common for both non-specific symptoms, and many less common cancers such as kidney, non-Hodgkin’s lymphoma, and pancreatic cancer.

Most cancers in the MDC were diagnosed at a late stage, which may reflect the systemic nature of some of the non-specific symptoms eligible for MDC referral. Even so, 21% of less common cancers were diagnosed at stage VII, with rates varying by tumour site but limited by insufficient numbers in some instances. Where site-specific data were available, early-stage diagnosis for pancreatic cancer was consistent with the national rate (23% MDC; 23% England), suggesting that the pathway may offer benefit for some tumour sites with very poor early-stage diagnosis.

The proportion of early-stage diagnosis was

16

57 days from GP urgent referral to treatment was recorded for less common cancers in the MDC, which is in line with the national 62-day wait standard. Treatment intervals varied by tumour site, with notably shorter median intervals reported for sarcoma, upper gastrointestinal, and ‘other’ cancers, but longer intervals identified for haematology and urology. A partial comparison against national 62-day wait compliance suggests the MDC is faster for oesophago-gastric cancers (75% MDC; 71% England), but moderately slower for other ‘selected’ cancer sites (60% MDC; 69% England). As the study relates to activity in pilot sites, it is plausible that these interval times may improve as the pathway matures and becomes fully embedded and resourced. Cumulatively, by reducing pre-referral activity and providing a swift overall time to treatment, the MDC may also lessen the chance of diagnosis via emergency presentation, which is common for both non-specific symptoms, and many less common cancers such as kidney, non-Hodgkin’s lymphoma, and pancreatic cancer.

Most cancers in the MDC were diagnosed at a late stage, which may reflect the systemic nature of some of the non-specific symptoms eligible for MDC referral. Even so, 21% of less common cancers were diagnosed at stage VII, with rates varying by tumour site but limited by insufficient numbers in some instances. Where site-specific data were available, early-stage diagnosis for pancreatic cancer was consistent with the national rate (23% MDC; 23% England), suggesting that the pathway may offer benefit for some tumour sites with very poor early-stage diagnosis.

The proportion of early-stage diagnosis was

16

The study relates to activity in pilot sites, it is plausible that these interval times may improve as the pathway matures and becomes fully embedded and resourced. Cumulatively, by reducing pre-referral activity and providing a swift overall time to treatment, the MDC may also lessen the chance of diagnosis via emergency presentation, which is common for both non-specific symptoms, and many less common cancers such as kidney, non-Hodgkin’s lymphoma, and pancreatic cancer.

Most cancers in the MDC were diagnosed at a late stage, which may reflect the systemic nature of some of the non-specific symptoms eligible for MDC referral. Even so, 21% of less common cancers were diagnosed at stage VII, with rates varying by tumour site but limited by insufficient numbers in some instances. Where site-specific data were available, early-stage diagnosis for pancreatic cancer was consistent with the national rate (23% MDC; 23% England), suggesting that the pathway may offer benefit for some tumour sites with very poor early-stage diagnosis.

The proportion of early-stage diagnosis was

16

The study relates to activity in pilot sites, it is plausible that these interval times may improve as the pathway matures and becomes fully embedded and resourced. Cumulatively, by reducing pre-referral activity and providing a swift overall time to treatment, the MDC may also lessen the chance of diagnosis via emergency presentation, which is common for both non-specific symptoms, and many less common cancers such as kidney, non-Hodgkin’s lymphoma, and pancreatic cancer.

Most cancers in the MDC were diagnosed at a late stage, which may reflect the systemic nature of some of the non-specific symptoms eligible for MDC referral. Even so, 21% of less common cancers were diagnosed at stage VII, with rates varying by tumour site but limited by insufficient numbers in some instances. Where site-specific data were available, early-stage diagnosis for pancreatic cancer was consistent with the national rate (23% MDC; 23% England), suggesting that the pathway may offer benefit for some tumour sites with very poor early-stage diagnosis.

The proportion of early-stage diagnosis was

16

The study relates to activity in pilot sites, it is plausible that these interval times may improve as the pathway matures and becomes fully embedded and resourced. Cumulatively, by reducing pre-referral activity and providing a swift overall time to treatment, the MDC may also lessen the chance of diagnosis via emergency presentation, which is common for both non-specific symptoms, and many less common cancers such as kidney, non-Hodgkin’s lymphoma, and pancreatic cancer.

Most cancers in the MDC were diagnosed at a late stage, which may reflect the systemic nature of some of the non-specific symptoms eligible for MDC referral. Even so, 21% of less common cancers were diagnosed at stage VII, with rates varying by tumour site but limited by insufficient numbers in some instances. Where site-specific data were available, early-stage diagnosis for pancreatic cancer was consistent with the national rate (23% MDC; 23% England), suggesting that the pathway may offer benefit for some tumour sites with very poor early-stage diagnosis.

The proportion of early-stage diagnosis was
lower than the national rate for cases of non-Hodgkin’s lymphoma (24% MDC; 30% England),\textsuperscript{37} and kidney cancer (29% MDC; 57% England).\textsuperscript{37} However, when interpreting this information, it is necessary to consider the strong association between non-specific symptoms and late-stage diagnosis. As the MDC focuses exclusively on this patient cohort, it will be disadvantaged in any comparison with national figures, within which this patient cohort will not be visible.

To gain a more comprehensive understanding of the MDC’s impact on pathway interval times and variation among differing diagnoses, further research, and the publication of cancer waiting time data for less common cancers will be required. It is important to gauge whether any benefits gained by faster times to diagnosis lead to earlier initiation of cancer treatment. Such work should also consider how current system capacity and access to specialist treatment may affect interval times, particularly given the specialist requirements for some rarer cancers. Further pathway evaluation is also merited on the balance of benefit and harm associated with diagnostic investigation, as only a minority of referrals with possible malignancy actually result in a cancer diagnosis. This additional information would contribute to the evidence base regarding non-specific symptoms and rarer cancers, and would directly inform the development and implementation of the rapid diagnostic centre model in England,\textsuperscript{38} which has evolved from the MDC approach. As these new pathways are established throughout England, it will be important to retain a focus on non-specific symptoms as a distinct cohort of patients, in order to build on the potential demonstrated in the MDC pilots. Such an approach may also offer an opportunity to develop a dedicated, integrated diagnostic interface between primary and secondary care, in support of the swift recognition, referral, and diagnosis of cancers presenting with non-specific symptoms.

\textbf{Acknowledgements}

The authors would like to thank the following people: Sean Duffy (West Yorkshire and Harrogate Cancer Alliance), Sara Hiom (former Director responsible at Cancer Research UK), Rosie Loftus (Macmillan Cancer Support), Carol Ferguson (West Yorkshire and Harrogate Cancer Alliance), and the National Awareness and Early Diagnosis Initiative Steering Group for forming and launching the MDC initiative. Thanks also to MDC patients; MDC project clinical teams from Airedale General Hospital, Manchester University NHS Foundation Trust (Wythenshawe Hospital), The Northern Care Alliance (Royal Oldham Hospital), Leeds St James University Hospital (Specialist Cancer Centre), North Middlesex University Hospital, University College London Hospital (Specialist Cancer Centre), Southend University Hospital, Queens (BHRUT), and the Royal Free Hospital, Oxford University Hospitals Trust (Specialist Cancer Centre); ACE Programme partners; NHS England; Cancer Research UK; and Macmillan Cancer Support.

\textbf{Open access}

This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licenses/by/4.0/).

\textbf{Discuss this article}

Contribute and read comments about this article: bjgp.org/letters
REFERENCES

1. Office for National Statistics. Cancer registration statistics, England: first release, 2016. 2018. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland2016 (accessed 18 Aug 2021).

2. Public Health England, Cancer52. Developments in data for rare and less common cancers. 2019. https://www.ndrs.nhs.uk/wp-content/uploads/2019/05/FINAL-SHARE-SLIDE-DECK-Development-in-data-for-rare-and-less-common-cancers-220519.pdf (accessed 18 Aug 2021).

3. Cancer52. Getting a better deal for people for rare and less common cancers: the next ten years. London: Cancer52, 2018.

4. Cancer52. A report from Cancer52 on National Cancer Intelligence Network data on rare and less common cancers. 2014. https://docs.wixstatic.com/vuglzc/e22f91_635eafa4f1e1844edf2ace7b0a601a12.pdf (accessed 18 Aug 2021).

5. Hamilton W. Five misconceptions in cancer diagnosis. Br J Gen Pract 2009; DOI: https://doi.org/10.3399/bjgp09X420860.

6. Koo MM, Hamilton W, Walter FM, et al. Symptom signatures and diagnostic timeliness in cancer patients: a review of current evidence. Neoplasia 2018; 20(2): 165–174.

7. Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract 2018; DOI: https://doi.org/10.3399/bjgp18X694169.

8. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 2015; 112(supp 1): S92–S107.

9. National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral. NICE: London, 2012.

10. Chapman D, Poirier V, Vulkan D, et al. First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer. Br J Cancer 2020; 123(5): 722–729.

11. Jørgensen SF, Ravn P, Thorsen S, Worm SW. Characteristics and outcomes of patients with non-specific symptoms and signs of cancer referred to a fast track cancer patient pathway: a retrospective cohort study. BMC Cancer 2017; 17(1): 809.

12. Nicholson BD, Hamilton W, Koshiaris C, et al. The association between unexpected weight loss and cancer diagnosis in primary care: a matched cohort analysis of 65,000 presentations. Br J Cancer 2020; 122(12): 1848–1856.

13. Nicholson BD, Hamilton W, O’Sullivan J, et al. Weight loss as a predictor of cancer diagnosis: a systematic review. Br J Gen Pract 2018; DOI: https://doi.org/10.3399/bjgp18X695801.

14. Schmidt-Hansen M, Berendse S, Hamilton W. The association between symptoms and bladder or renal tract cancer in primary care: a systematic review. Br J Gen Pract 2015; DOI: https://doi.org/10.3399/bjgp15X687421.

15. Lyratzopoulos G, Neal RD, Barbiere JM, et al. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the National Cancer Diagnosis Audit. Br J Gen Pract 2018; DOI: https://doi.org/10.3399/bjgp17X764169.

16. Fuller E, Fitzgerald K, Horn S. Accelerate, Coordinate, Evaluate Programme: a new approach to cancer diagnosis. Br J Gen Pract 2016; DOI: https://doi.org/10.3399/bjgp16X684457.

17. Panagias KS. Clinical trial design for rare cancers: why a less conventional route may be required. Expert Rev Clin Pharmacol 2015; 8(6): 661–663.

18. Nicholson BD, Hamilton W, Koshiaris C, et al. The association between unexpected weight loss and cancer diagnosis in primary care: a matched cohort analysis of 65,000 presentations. Br J Cancer 2020; 122(12): 1848–1856.

19. National Cancer Registration and Analysis Service. Routes to diagnosis 2006–2015: a handbook for local health and care systems. 2019. https://www.ncrg.org.uk/sites/default/files/expected_features_of_the_mdc_model_edit.pdf (accessed 18 Aug 2021).

20. NHS Cancer Waiting Times data collection (CWT). 2021. https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/cancerwaitingtimestatisticsengland/.

21. NHS England. Cancer Waiting Times annual report, 2019–20. 2020. https://www.england.nhs.uk/wp-content/uploads/2018/04/implementing-a-timed-oesophago-gastric-cancer-pathway.pdf (accessed 18 Aug 2021).

22. NHS England. Implementing a timed oesophago-gastric cancer diagnostic pathway. A handbook for local health and care systems. 2019. https://www.england.nhs.uk/wp-content/uploads/2018/04/implementing-a-timed-oesophago-gastric-cancer-pathway.pdf (accessed 18 Aug 2021).

23. Office for National Statistics. Cancer survival in England: adult, stage at diagnosis and childhood — patients followed up to 2018. 2019. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/stageatdiagnosisandchildhoodpatientsfollowedupto2018 (accessed 18 Aug 2021).

24. NHS England. National Cancer Patient Experience Survey: national results summary. 2020. https://www.ncpes.co.uk/wp-content/uploads/2020/06/CPES-2019-National-Report_V1.pdf (accessed 18 Aug 2021).

25. NHS England, NHS Improvement. Rapid diagnostic centres: vision and 2019/20 implementation specification. 2019. https://www.england.nhs.uk/wp-content/uploads/2019/07/rdc-vision-and-1920-implementation-specification.pdf (accessed 18 Aug 2021).

26. Shepherd E, Neal R, Rose P, et al. Clinical features of kidney cancer in primary care: a case-control study using primary care records. Br J Gen Pract 2013; DOI: https://doi.org/10.3399/bjgp13X665215.

27. Parag A, Morgan C, McDonald N, et al. Remodelling the cancer care journey to deliver timely care: from cure to care. BMJ 2014; 349: g6802.

28. NHS Digital. Cancer Waiting Times data collection (CWT). 2021. https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/cancerwaitingtimesdatacollection/.

29. NHS England. Cancer Waiting Times annual report, 2019–20. 2020. https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times-cow/annual-reports/cancer-waiting-times-annual-report-2019-20 (accessed 18 Aug 2021).

30. National Cancer Registration and Analysis Service. Routes to diagnosis. 2006–2016 workbook. 2020. http://www.ncin.org.uk/publications/routes_to_diagnosis (accessed 7 Sep 2021).

31. Shepherd E, Neal R, Rose P, et al. Clinical features of kidney cancer in primary care: a case-control study using primary care records. Br J Gen Pract 2013; DOI: https://doi.org/10.3399/bjgp13X665215.

32. Basu Roy, Bouxier C, Ramage JK, et al. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer 2018; 18(1): 1122.

33. NHS England, NHS Improvement. Rapid diagnostic centres: vision and 2019/20 implementation specification. 2019. https://www.england.nhs.uk/wp-content/uploads/2019/07/rdc-vision-and-1920-implementation-specification.pdf (accessed 18 Aug 2021).